摘要
基于超高效液相-离子阱-静电场轨道肼质谱(UPLC-LTQ-Orbitrap MS)技术分析鉴定四妙勇安汤水煎液的化学成分。采用UPLC BEH C;色谱柱(2.1 mm×100 mm,1.7μm),以乙腈-0.1%甲酸水为流动相进行梯度洗脱,流速0.4 mL·min^(-1)。质谱使用加热电喷雾离子源(HESI),负离子模式采集数据。通过对照品比对总结各类成分裂解规律,结合精确相对分子质量和一二级质谱信息,以及相关文献和MassBank、HMDB等数据库的数据支持,从四妙勇安汤中鉴定出72个化学成分,包括30个环烯醚萜苷类,9个有机酸类,15个黄酮类,10个苯丙素类,7个三萜类和1个糖类成分。该研究建立的四妙勇安汤化学成分的鉴定方法较为全面、快速、准确,总结了四妙勇安汤各类型成分的裂解规律,为其物质基础和药效作用机制的阐明奠定基础。
This study aims to identify the chemical constituents of Simiao Yong′an Decoction based on ultra-performance liquid chromatography coupled with linear quadrupole ion trap-orbitrap mass spectrometry(UPLC-LTQ-Orbitrap-MS).The elution was performed through a UPLC BEH C;column(2.1 mm×100 mm,1.7μm)with the mobile phase of water(containing 0.1%formic acid)-acetonitrile at a flow rate of 0.4 mL·min^(-1).LTQ-Orbitrap-MS with heat electrospray ion(HESI)source was employed to collect MS fragment information in the negative ion mode.A total of 72 compounds were identified based on reference substance comparison,fragmentation rules,accurate molecular weight,related reports and databases(MassBank and HMDB),including 30 iridoid glycosides,9 organic acids,15 flavonoids,10 phenylpropanoids,7 triterpenoids,and 1 saccharide.The method established in this study is comprehensive,rapid,and accurate,which can help summarize the fragmentation rules of constituents and provide reference for revealing the active constituents and pharmacodynamic mechanism of Simiao Yong′an Decoction.
作者
孙克寒
杨会
王淑琪
王春国
杨漫芳
高照
许心蕊
聂波
SUN Ke-han;YANG Hui;WANG Shu-qi;WANG Chun-guo;YANG Man-fang;GAO Zhao;XU Xin-rui;NIE Bo(Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 100029,China;Jiangxi Qingfeng Pharmaceutical Co.,Ltd.,Ganzhou 341008,China;Beijing Institution of Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100029,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2022年第10期2658-2667,共10页
China Journal of Chinese Materia Medica
基金
国家“重大新药创制”科技重大专项(2017ZX09304019)。
